Jagsonpal Pharma and Redington Report Strong Q1 FY27 Profit and Revenue Growth
Jagsonpal Pharmaceuticals reported a 22.15% year-on-year rise in Q1 FY27 net profit to Rs 13.18 crore, with revenue increasing 8.76% to Rs 82.23 crore, aided by improved medical representative productivity and the acquisition of Aequitas. Meanwhile, Redington Ltd posted record Q1 FY27 results, with net profit surging 76.6% to Rs 486 crore and revenue rising 34.6% to Rs 34,922 crore. Growth was broad-based, driven by strong performance in India, the Middle East, and Africa, supported by enterprise deals and demand in cloud, cybersecurity, and technology solutions.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (76/100). Lens Score 39/100.
Outlets measured: economictimes, businessstandard, businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 30 Jul, 04:38 am. Other outlets followed.